重组人尿激酶原静脉溶栓治疗STEMI的疗效和安全性研究  

Efficacy and safety of thrombolytic therapy using recombinant prourokinase in patients with acute myocardial infarction with ST-segment elevation

作　　者：高宏波[1] 郭欣 王永进 卫娇娜[1] 丁钰轩[1] 杜亚坤 白晓君[3] 赵宽 黄新亮 GAO Hong-bo;GUO Xin;WANG Yong-jin;WEI Jiao-na;DING Yu-xuan;DU Ya-kun;BAI Xiao-jun;ZHAO Kuan;HUANG Xin-liang(Department of Cardiology,Hanzhong People’s Hospital,Hanzhong 723000,Shaanxi,China;Department of Cardiology,Hospital of Unit 96605,Tonghua 134001,Jilin,China;Department of Cardiology,First Affiliated Hospital,Xi’an Jiaotong University,Xi’an 710061,Shaanxi,China;Department of Cardiology,Hanzhong 3201 Hospital,Hanzhong 723000,Shaanxi,China)

机构地区：[1]汉中市人民医院心内科,陕西汉中723000 [2]解放军96605部队医院心血管内科,吉林通化134001 [3]西安交通大学第一附属医院心内科,陕西西安710061 [4]汉中市3201医院心内科,陕西汉中723000

出　　处：《心脏杂志》2022年第3期289-292,共4页Chinese Heart Journal

摘　　要：目的观察重组人尿激酶原(rhPro-UK)经静脉溶栓治疗急性ST段抬高型心肌梗死(STEMI)的临床疗效和安全性。方法选择汉中市人民医院静脉溶栓治疗的STEMI患者,根据患者溶栓药物不同分为重组人尿激酶原组(n=206)和尿激酶组(n=92),收集两组患者的基线资料和冠状动脉造影资料,比较两组患者临床冠脉再通率、冠脉造影TIMI≥2级开通率、主要出血事件和其他并发症发生率。结果与尿激酶组患者比较,重组人尿激酶原组临床再通率[164(79.62%)vs.52(63.04%),P<0.01]和TIMI≥2级开通率[149(82.78%)vs.50(65.79%),P<0.01]显著提高,且主要出血事件[15(7.8%)vs.14(15.22%),P<0.05]和并发症发生率[5(2.3%)vs.8(8.70%),P<0.05]显著降低。结论重组人尿激酶原静脉溶栓治疗STEMI患者血管再通率优于尿激酶,且出血事件及其他并发症发生率低。AIM To observe the clinical efficacy and safety of thrombolytic therapy using recombinant prourokinase(rhPro-UK)in patients with acute myocardial infarction with ST-segment elvation(STEMI).METHODS STEMI patients with thrombolysis were selected and were divided into recombinant prourokinase group(n=206)and urokinase group(n=92).Baseline data of the two groups were collected,and clinical coronary recanalization rate,coronary angiography TIMI≥2 opening rate,major bleeding events and complication rate were compared between the two groups.RESULTS Compared with those in urokinase group,the clinical recanalization rate[164(79.62%)vs.52(63.04%),P<0.01]and the opening rate of TIM≥2[149(82.78%)vs.50(65.79%),P<0.01]were significantly improved in recombinant prourokinase group,while the major bleeding events[15(7.8%)vs.14(15.22%),P<0.05]and the complication rate[5(2.3%)vs.8(8.70%),P<0.05]were significant reduced.CONCLUSION Recombinant prourokinase has a higher rate of thrombolytic vascular recanalization and a lower incidence of bleeding events and complications.

关 键 词：重组人尿激酶原 静脉溶栓 急性ST段抬高型心肌梗死 

分 类 号：R541.4[医药卫生—心血管疾病]